The WWR-K research reactor at Kazakhstan’s Institute of Nuclear Physics (INP) is expected to remain in operation until at least 2040. To achieve this, the institute plans to seek an extension of the reactor’s service life through the International Atomic Energy Agency (IAEA) in the coming years. The announcement was made by INP Director General Sayabek Sakhiev during a press tour for journalists.
Over the next three to four years, we will apply to the IAEA to extend the reactor’s operational lifespan by another 10 to 15 years. If we secure such an extension in 2030, it would allow the reactor to operate until 2040-2045. What happens after that will depend on future developments," Sakhiev said.
He recalled that in September 2025, Kazakh President Kassym-Jomart Tokayev instructed the government to consider the construction of new research reactors at the Institute of Nuclear Physics.
The institute expects that by the time the current reactor reaches the end of its service life, a new research reactor will already be operating in Kazakhstan. The existing facility could then be used to train specialists for the nuclear industry, including personnel for the country’s future nuclear power plant.
Sakhiev also stressed the importance of uninterrupted production of radiopharmaceuticals used in the diagnosis and treatment of cancer. The reactor currently operates on a cycle of three weeks of operation followed by one week of shutdown and undergoes two months of scheduled maintenance during the summer.
If a second research reactor is built, we will be able to distribute this workload and avoid interruptions," he said.
The Institute of Nuclear Physics is Kazakhstan’s only research organization dedicated to the peaceful use of atomic energy that carries out a full cycle of scientific research and experimental design work, including fundamental and applied research, technology development and production.
The institute conducts testing of materials for next-generation nuclear reactors and fusion facilities, applies nuclear technologies in industry, scientific research and medicine, and produces essential radiopharmaceuticals for the diagnosis and treatment of cancer. The INP currently operates 12 major experimental facilities, including the WWR-K research reactor, a critical assembly, storage facilities for radioactive waste and spent ionizing radiation sources, as well as six charged-particle accelerator complexes.
The WWR-K reactor is Kazakhstan’s only multipurpose reactor. In addition to fundamental nuclear physics and materials science research and in-reactor testing, it is used for the production of medical radioisotopes, gamma radiation sources for industry, neutron activation analysis and material modification through neutron irradiation.
The WWR-K reactor and the Cyclone-30 cyclotron form the basis of Kazakhstan’s only GMP-accredited production facility for reactor-based radiopharmaceuticals. The institute currently manufactures and supplies three radiopharmaceuticals to medical centers across the country, including products based on iodine-131 and molybdenum-99/technetium-99m.
Iodine-131 is used to treat thyroid diseases, including cancer, while technetium-99m is widely used in the diagnosis of diseases affecting virtually all human organs and body systems. Technetium-99m generators are also produced by the institute using a patented technology.
Overall, the institute’s product line covers key isotopes used in the diagnosis of cancer and cardiovascular diseases and in the treatment of thyroid cancer. The INP supplies approximately 85% of Kazakhstan’s demand for radiopharmaceuticals.
The Cyclone-30 facility is designed for the industrial-scale production of radioisotopes and is currently operating at near-full capacity producing fluorine-18 for PET diagnostics, demand for which continues to grow steadily in Kazakhstan.
INP products are used annually in the treatment and diagnosis of more than 18,000 patients, while industrial radioisotopes are exported to Europe, the United States and Central Asian countries.
The institute is also implementing investment projects aimed at localizing the production of strategically important radioisotopes, including molybdenum-99 produced through the fission method and lutetium-177, while expanding its commercial activities.
The INP is the country’s sole producer of ionizing radiation sources, including cobalt-57, iridium-192 and antimony-124. Cobalt-57 is currently exported to Germany, France and Russia.
The institute operates training centers that have educated more than 4,500 specialists and plans to open a regional training center for nuclear forensics in 2026. It also conducts research in radiation ecology and monitors radiation-hazardous facilities.